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Aim: Hypoglycemia in childhood is very rare and can be caused by genetic mutations or
insulin-secreting neoplasms. Postprandial hypoglycemia has previously been associated with
insulin receptor (INSR) gene mutations. We aimed to identify the cause of postprandial hypo-
glycemia in a 10-year-old boy.
Subjects: We studied the symptomatic proband and his apparently asymptomatic mother and
elder brother. All of them were lean.
Methods: Metabolic screening of the proband included a 5-hour oral glucose tolerance test
(OGTT), angio-magnetic resonance imaging, and 18F-dihydroxyphenylalanine positron emission
tomography/computed tomography imaging of the pancreas. INSR gene sequencing and
in vitro functional studies of a novel INSR mutation were also undertaken.
Results: Fasting hyperinsulinemia was detected during metabolic screening, and 5-hour OGTT
showed hypoglycemia at 2400 in the proband, his mother, and brother. Pancreatic imaging
showed no evidence of neoplasia. Acanthosis nigricans with high fasting insulin levels in the
proband suggested severe insulin resistance and prompted INSR gene sequencing, which
revealed the novel, heterozygous p.Phe1213Leu mutation in the patient and his family mem-
bers. In vitro studies showed that this mutation severely impairs insulin receptor function by
abolishing tyrosine kinase activity and downstream insulin signaling.
Conclusions: The identification of etiological cause of hypoglycemia in childhood may be chal-
lenging. The combination of fasting hyperinsulinemia with acanthosis nigricans in a lean subject
with hypoglycemia suggests severe insulin resistance and warrants INSR gene screening.
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1 | INTRODUCTION
Hyperinsulinemic hypoglycemia (HH) is a rare condition that has mul-
tiple causes in adults, including pancreatic beta-cell tumors and circu-
lating insulin or insulin receptor autoantibodies.1 In neonates,
however, HH is more common and generally has a genetic etiology,
being associated with mutations in genes involved in the regulation
of insulin secretion, such as ABCC8, KCNJ11, GLUD1, GCK, HADH,
SLC16A1, HNF4A, and HNF1A.2 Exercise-induced HH can be caused
by mutations in the promoter of monocarboxylate transporter
1 (MCT1).3 Differential diagnosis of HH with onset in childhood or
adolescence may be more challenging due to the presence of either
genetic4,5 or tumoral6–8 etiologies. Dominant-negative, heterozygous
mutations in the tyrosine-kinase domain of the insulin receptor gene
(INSR), conversely, usually cause extreme hyperinsulinemia with either
normal or increased blood glucose concentrations. However, scat-
tered reports attest that INSR mutations may sometimes also cause
familial hyperinsulinemia with postload hypoglycemia.9,10
In this report, we describe a lean child who presented with post-
load, reactive hypoglycemia as the only symptom. However, acantho-
sis nigricans, along with high levels of fasting insulin with normal
plasma glucose, suggested severe insulin resistance. A novel INSR
mutation (F1213L) was identified in the proband and his mother and
brother, who also showed reactive hypoglycemia and prolonged
(5 hours) oral glucose.
2 | METHODS
Parental informed consent was obtained for all medical procedures.
Clinical studies were performed in accordance with the Declaration
of Helsinki.
2.1 | Metabolic investigations
The proband underwent routine investigation for HH, including
determination of plasma concentrations of amino acids and urinary
organic acids, free fatty acids, beta-hydroxybutyric acid, and carnitine
with standard methods. Cortisol, adrenocorticotropic hormone
(ACTH) and growth hormone (GH) levels levels, and fasting insulin
were also assessed using standard clinical laboratory methods. A 5-h
oral glucose tolerance test (OGTT) with assay of glucose, insulin, and
C-peptide was performed for the proband and his first-degree rela-
tives with a history of symptoms of postprandial hypoglycemia.
2.2 | Pancreatic imaging
Angio-magnetic resonance imaging (angio-MRI) and 18F-
dihydroxyphenylalanine (18F-DOPA) positron emission tomography/
computed tomography (PET/CT; GE Healthcare 2.1753) were per-
formed in the proband according to standard protocols.
2.3 | Genetic screening
DNA sequencing of INSR gene was performed as described
previously.11
2.4 | Assessment of INSR expression and signaling
Site-directed mutagenesis was used to introduce the L1213 mutation
into the C-terminal myc-tag wild-type INSR expression vector
pCDNA5/FRT/TO/hINSR. Chinese hamster ovary (CHO) Flp-In cells
(Invitrogen) were transfected with either pCDNA5/FRT/TO/hINSR or
pCDNA5/FRT/TO/hINSR-L1213 and pOG44 using Lipofectamine
2000 (Invitrogen). The polyclonal populations surviving Hygromycin B
selection were used for experiments. To assess insulin receptor
expression, CHO Flp-In cells stably overexpressing either wild type or
F1213L mutant human INSR were lysed, and 25 μg of total protein
was resolved by SDS-PAGE before transfer to nitrocellulose and
Western blotting for INSR β-subunit (Santa Cruz Biotech: sc-711) and
β-actin (Cell Signaling Technology: 4970). Cell-surface expression of
the insulin receptor was determined by flow cytometry using anti-
INSR α-subunit antibody 83-14 (a gift from Professor Ken Siddle,
University of Cambridge), with negative isotype Immunoglobulin G
(IgG; Sigma)-labeled cells as a negative control. Finally, to evaluate
insulin-induced receptor autophosphorylation CHO Flp-In cells over-
expressing either wild-type or F1213L, human INSR were serum-
starved overnight prior to stimulation with increasing amounts of
insulin for 10 minutes. Cells were lysed, and myc-tagged INSR were
immunocaptured onto 96-well plates with anti-myc antibody 9E10
(a gift from Professor Ken Siddle, University of Cambridge) before
incubation with europium-labeled PY20 antibody (Perkin Elmer:
AD0038) to detect phosphorylated tyrosine residues. DELFIA-
enhancement solution (Perkin Elmer) was added and time-resolved
fluorescence measured (Ex: 340 nm/Em: 615 nm).
3 | RESULTS
3.1 | Clinical presentation
The proband was born at 38 weeks of gestation with a birthweight of
2780 g (25th centile). At the age of 10, the patient experienced
TABLE 1 5-h OGTT data in the proband and his family members
carrying the INSR/F1213L
Proband 11 y—BMI 19.8 (66th centile)
Time (min) 0 60 120 180 240 270
Plasma glucose
(mg/mL)
81 98 111 100 55 56
Serum insulin
(mU/mL)
23,9 265 304 215 86,2 24,7
Mother 36 y—BMI 19
Time (min) 0 60 120 180 240 270
Plasma glucose
(mg/mL)
90 156 102 73 35 67
Serum insulin
(mU/mL)
25,2 173 264 198 42,6 16,5
Brother 19 y—BMI 17
Time (min) 0 60 120 180 210 270
Plasma glucose
(mg/mL)
77 130 125 89 40 51
Serum insulin
(mU/mL)
27,2 253 >300 >300 84,7 34,7
Abbreviation: BMI, body mass index.
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frequent episodes of tremors occurring about 2 hours after meals
and resolving quickly on consumption of simple carbohydrates. When
in her 20s, the proband’s mother, now 38 years old, had experienced
symptoms suggestive of hypoglycemia, including cold sweating and
trembling also occurring 1 to 2 hours postprandially, particularly after
simple carbohydrate-based food. Maternal grandparents were diag-
nosed with type 2 diabetes, but neither the mother nor the maternal
grandparents showed signs of insulin resistance.
The proband was first evaluated metabolically when he was
11 years old. His weight and height were 35.8 kg and 136.5 cm,
respectively; his body mass index was 19.8; and Tanner stage was
1. The presence of acanthosis nigricans in the axillae and neck was
recorded. The patient’s fasting insulin concentration was 97 μU/mL
at first determination, and on 5-hour OGTT, he developed symptoms
of hypoglycemia with a plasma glucose concentration of 55 mg/dL at
240 minutes (Table 1) and an insulin peak value of 304 μU/mL at
120 minutes (Table 1). Counter-regulatory hormones measured
during OGTT-induced hypoglycemia showed no secretory deficit
(cortisol 574 nmol/L; reference values: 138-690; ACTH 136 ng/L;
reference values 10-50; GH 4,21 μg/L; reference values 0-8). non
esterified fatty acids (NEFA) 3OH-butyric acid, carnitine, acylcarni-
tines, plasma amino acids, and urinary organic acids were all normal.
An angio-MRI and an 18F-DOPA PET/CT scan, performed to detect/
exclude insulinoma, a rare cause of recurrent hypoglycemia in child-
hood, did not reveal any abnormality of the pancreas (Figure S1).
The patient was given a diet devoid of simple carbohydrates,
reducing the frequency of hypoglycemia to less than 1 per month;
however, continuous glucose monitoring (Dexcom G4) showed that
glucose levels were below 80 mg/dL for 60% of the period observed,
with values down to 50 mg/dL at night. Concomitant blood glucose
concentration on self-monitoring was 60-78 mg/dL; Figure 1). The
combination of fasting hyperinsulinemia and acanthosis nigricans in a
lean subject with anecdotal evidence of hypoglycemia in the mother
prompted screening of the INSR gene and identified the heterozygous
Statistics 
Average Glucose 78 mg/dL 
10 of 30 Days Sensor Usage 
2.6 Calibrations / day 
Standard Deviation ± 20 mg/dL 
2 % High 
38 % Target 
60 % Low 
Target Range 80 - 130 mg/dL 
FIGURE 1 A 5-day recording of glucose
values by CGM, each identified by a
different color. Note that low glucose
values are consistently seen at night
(10:00 PéM—6:00 AM)
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c.3637T>C [p.Phe1213Leu (F1213L)] mutation. This variant was not
present in the HGMD database or the ExAC browser and was found
in the proband’s mother and brother, who also showed fasting hyper-
insulinemia and low plasma glucose concentration at 240 minutes of
OGTT (35 and 40 mg/dL, respectively; Table 1). However, neither
the patient’s mother nor the brother showed any clinical symptoms
or signs of hypoglycemia. A repeat 5-hour OGTT, performed in the
proband 2 years later, confirmed fasting hyperinsulinemia (27 mU/L)
and low glucose levels at the end of the test (3000: 51 mg/dL).
The effect of the mutation on receptor expression and function
was examined in CHO cells. Protein expression of the L1213 mutant
receptor was similar to that of the wild-type (F1213) receptor
(Figure 2A), and moreover, a mutant insulin receptor was detectable
at the cell surface at the same level as wild-type receptor (Figure 2B).
In contrast, autophosphorylation of tyrosine residues in the receptor
beta subunit was abolished in L1213 INSR, even at maximal insulin
concentrations (Figure 2C, triangles), indicating that phenylalanine
1213 is fundamental for downstream signaling by the insulin
receptor.
4 | DISCUSSION
HH in childhood encompasses congenital HH (of mostly genetic etiol-
ogy)2,6,7 admixed with a low prevalence of more “adult” HH entities,
such as insulinoma.1 Unfortunately, criteria based on the temporal
relationship of hypoglycemia to meals is not useful in excluding insuli-
noma, a condition that is exceedingly rare in children.6,7 When an
insulin-secreting tumor is among the possible diagnoses, 18 an F-
DOPA PET-CT scan is recommended to localize the lesion.6,12 Once
insulinoma is excluded, as in our case, a genetic cause may be
considered. Our proband experienced hypoglycemic episodes in
childhood, well beyond what is usually observed in congenital and
recessive forms of HH.2 In addition, his mother reported that she had
symptoms highly suggestive of postprandial hypoglycemia. While
these findings were suggestive of dominant forms of HH, such as that
caused by glucokinase (GCK) mutations,13,14 individuals with acti-
vated GCK mutations characteristically present with fasting, not post-
prandial, hypoglycemia, and they do not have signs of insulin
resistance.13,14
Heterozygous mutations of INSR have previously been linked to
familial, autosomal-dominant HH.9,10 In both previously reported fami-
lies, the index case was a lean female with postprandial hypoglycemia,
but only 1 showed typical clinical signs of severe insulin resistance,
such as hirsutism, acanthosis nigricans, and acne, despite a biochemical
profile consistent with severe insulin resistance.10,15,16 Thus, the hall-
mark of autosomal-dominant “HH” associated with dominant-negative
INSR mutations seems to be postload hypoglycemia (either symptom-
atic or not), with biochemical evidence of severe insulin resistance but
low clinical expression of that severe insulin resistance, rendering HH
the sentinel clinical presentation [9,17i, present study].
The precise mechanism of hypoglycemia in individuals with
insulin-receptor mutations is still debated. Paradoxical fasting hypo-
glycemia is a feature of 2 congenital severe insulin resistance (SIR)
syndromes, namely Donohue syndrome (erstwhile “leprechaunism”)
and Rabson-Mendenhall syndrome, both caused by biallelic mutations
of INSR.15,18 In a milder form of SIR, known as type A insulin resis-
tance (Type A IR), usually associated with dominant-negative, hetero-
zygous INSR mutations, hypoglycemia commonly occurs 3 to 4 hours
after meals.18 Type A IR is typically diagnosed in adolescent females
with acanthosis nigricans, hirsutism, and menstrual cycle
disturbances,11,16–18 whereas it is probably underdiagnosed in males
in the absence of signs of hyperandrogenism.17,18 In all types of SIR,
FIGURE 2 Expression and autophosphorylation of INSR F1213 (WT) and L1213 variant. A, Western blot of lysates from CHO Flp-In cells stably
expressing F1213 (WT) or L1213 INSR variant as indicated. In INSR β-subunit blot, upper bands are pro-INSR, and lower bands are mature
processed β-subunits, as indicated. B, Cell surface expression of INSR in CHO Flp-In cells expressing either F1213 (solid line) or L1213 (dashed
line) labeled with anti-INSR antibody 83-14. Negative isotype control IgG-labeled cells are depicted in the gray shaded area. A shift to the right
of the negative control peak indicates positive cell surface expression of INSR. C; CHO Flp-In cells stably expressing F1213 (black line, circles) or
L1213 INSR variant (gray line, triangles) were serum-starved overnight prior to stimulation with increasing amounts of insulin for 10 minutes.
Cells were then lysed and myc-tagged INSR immunocaptured onto 96-well plates and then incubated with europium-labeled PY20 antibody to
detect phosphorylated tyrosine residues using time-resolved fluorescence. Error bars are shown when greater than the size of the symbols, and
data points are the mean  SEM from duplicate samples from 3 independent experiments. EC50 insulin-stimulated INSR F1213: 4.2 nM (95% CI
2.6-6.7 nM); EC50 insulin-stimulated INSR L1213: unable to be determined
4 INNAURATO ET AL.
an impairment of hepatic insulin clearance due to the INSR defect
(or to hepatic steatosis) and consequent hyperinsulinemia appear to
be likely contributors to the pathogenesis of hypoglycemia. In our
patient, in a previous case,10 Continuous Glucose Monitoring System
(CGMS) documented low glucose levels during the night. Thus, we
hypothesize that impaired hepatic glycogen synthesis may contribute
to less efficient hepatic glucose production during the fasting state,
although no formal proof of this mechanism has been provided in our
study. To date, 5 mutations in the INSR tyrosine kinase domain
(Arg1201Gln, Arg1201Trp, Pro1205Leu, Phe1213Leu, and
Trp1273Ter, according to nomenclature that includes 27 amino acids
of signal peptide) (References 9–11,17, present study, 19) have been
found to be associated with postprandial hypoglycemia with presen-
tation during childhood and adulthood, but no studies have been per-
formed to address the question of INSR structure-function specificity
of these mutations in causing this condition.
In conclusion, in evaluating childhood HH, the possibility of insu-
lin resistance should be considered, and clinical and biochemical evi-
dence should be sought. INSR screening should be considered if
postprandial/postload hypoglycemia with inappropriately high insulin
levels are found in an otherwise apparently healthy and lean subject.
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